Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
13.02
+0.09 (0.66%)
Nov 26, 2025, 4:00 PM EST - Market closed
Benitec Biopharma Employees
Benitec Biopharma had 19 employees as of June 30, 2025. The number of employees increased by 3 or 18.75% compared to the previous year.
Employees
19
Change (1Y)
3
Growth (1Y)
18.75%
Revenue / Employee
n/a
Profits / Employee
-$2,201,211
Market Cap
440.72M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 19 | 3 | 18.75% |
| Jun 30, 2024 | 16 | -2 | -11.11% |
| Jun 30, 2023 | 18 | 0 | - |
| Jun 30, 2022 | 18 | 4 | 28.57% |
| Jun 30, 2021 | 14 | 0 | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BNTC News
- 13 days ago - Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 22 days ago - Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering - GlobeNewsWire
- 22 days ago - Benitec Biopharma Inc. Announces Proposed Public Offering - GlobeNewsWire
- 24 days ago - Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 - GlobeNewsWire
- 25 days ago - Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewsWire
- 2 months ago - Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update - GlobeNewsWire
- 8 months ago - Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer - Seeking Alpha
- 8 months ago - Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering - GlobeNewsWire